Last reviewed · How we verify
Telmisartan plus Metformin
Telmisartan blocks angiotensin II receptors to lower blood pressure, while metformin reduces hepatic glucose production and improves insulin sensitivity to control blood sugar.
Telmisartan blocks angiotensin II receptors to lower blood pressure, while metformin reduces hepatic glucose production and improves insulin sensitivity to control blood sugar. Used for Hypertension in patients with type 2 diabetes mellitus, Cardiovascular risk reduction in hypertensive diabetic patients.
At a glance
| Generic name | Telmisartan plus Metformin |
|---|---|
| Sponsor | Third Military Medical University |
| Drug class | ARB + Biguanide combination |
| Target | Angiotensin II type 1 receptor (AT1R); mitochondrial glycerophosphate dehydrogenase |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular / Endocrinology |
| Phase | FDA-approved |
Mechanism of action
Telmisartan is an angiotensin II receptor blocker (ARB) that reduces vasoconstriction and aldosterone secretion, lowering blood pressure. Metformin is a biguanide that decreases hepatic gluconeogenesis and enhances peripheral glucose uptake and insulin sensitivity. This combination addresses both hypertension and hyperglycemia in patients with concurrent conditions.
Approved indications
- Hypertension in patients with type 2 diabetes mellitus
- Cardiovascular risk reduction in hypertensive diabetic patients
Common side effects
- Dizziness
- Fatigue
- Gastrointestinal disturbance (metformin-related)
- Hyperkalemia
- Diarrhea
Key clinical trials
- To Compare the Effects of Herbal Medicines With Traditional Allopathic Medicines in Cases of Patients With Metabolic Syndrome (NA)
- Effects of ROSIglitazone on Inflammatory Markers and Adipokines in Diabetic Patients Using an Angiotensin Receptor Blocker (TELmisartan) - The ROSITEL Study (NA)
- A Randomized, Double-Blind, Active Control Trial Comparing Effects of Telmisartan, Candesartan and Amlodipine, Alone or Plus Metformin, on Non-Diabetic, Obese Hypertensive Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Telmisartan plus Metformin CI brief — competitive landscape report
- Telmisartan plus Metformin updates RSS · CI watch RSS
- Third Military Medical University portfolio CI